ClinicalTrials.gg
CompletedNCT01979016Updated Mar 18, 2020Results posted

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

A Phase 2 interventional study of Dupilumab and Placebo in Atopic Dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
29th of 50
54 · median 75
Started
2013
with 2 others
Phase 2
7 of 50
none open now
Registered
6th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 29th largest by enrollment, is one of 3 that started in 2013, is one of 7 in phase 2, and was the 6th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, 18 years or older;
  2. Chronic AD that had been present for at least 3 years before the screening visit;
  3. Patients with documented recent history (within 6 months before the screening visit) of inadequate response to out-patient treatment with topical medications, or for whom topical treatments were otherwise inadvisable;
  4. Willing and able to comply with all clinic visits and study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior participation in a Dupilumab clinical trial;
  2. Treatment with an drug within 8 weeks or within 5 half-lives before the baseline visit;
  3. The following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, will likely require such treatment(s) during the first 4 weeks of study treatment:

    • Systemic ;
    • /immunomodulating drugs;
    • Phototherapy for AD;
  4. Treatment with topical corticosteroids, tacrolimus and/or pimecrolimus within 1 week before the baseline visit;
  5. Treatment with certain biologics;
  6. Regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks before the baseline visit;
  7. Planned major surgical procedure during the participant's participation in this study;
  8. Participant was a member of the investigational team or his/her immediate family;
  9. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit
  10. Pregnant or breast-feeding women or women planning to become pregnant or breastfeed during the study;

Note: The information listed above is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial therefore not all inclusion/exclusion criteria are listed.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Placebo qw

    Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.

    Drug: Placebo · Other: Background treatment

  • Experimental
    Dupilumab 200 mg qw

    Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.

    Drug: Dupilumab · Other: Background treatment

Interventions

  • Also known as: REGN668, SAR231893, Dupixent

  • DrugPlacebo

    Matching placebo

  • OtherBackground treatment

    Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).

    Also known as: Topical emollient

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue medication use were set to missing and missing values imputed by last observation carried forward (LOCF).

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16

    IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were considered as non-responders.

    Time frame: Week 16

  2. Percentage of Participants Who Achieved IGA Score Reduction From Baseline of ≥2 Points at Week 16

    IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Participants with reduction in IGA score from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as non-responders.

    Time frame: Baseline to Week 16

  3. Absolute Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  4. Percent Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  5. Absolute Change From Baseline in EASI Score to Week 16

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  6. Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16

    SCORAD was a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  7. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16

    SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  8. Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score ( EASI-50, EASI-75, and EASI-90 Respectively) at Week 16

    EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranged from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% respectively, overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

    Time frame: Baseline to Week 16

  9. Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16

    SCORAD was a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% respectively, overall improvement in SCORAD score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing SCORAD score at Week 16 were counted as non-responders.

    Time frame: Baseline to Week 16

  10. Absolute Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16

    POEM was a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  11. Percent Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16

    POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  12. Change From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) to Week 16

    Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

  13. Changes From Baseline in GISS Cumulative Score to Week 16

    Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

    Time frame: Baseline to Week 16

07

Results

Posted Mar 18, 2020

Participant flow

The study was conducted at 5 sites in USA and Canada between 05 December 2013 and 30 January 2015. A total of 66 participants were screened in the study.

Participant flow — Overall Study
MilestonePlacebo qwDupilumab 200 mg qw
Started2727
Completed2526
Not completed21
Withdrew: Withdrawal by subject20
Withdrew: Adverse event01

Outcome measures

PrimaryPercent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema (E), infiltration (I), excoriation (Ex) and lichenification (L) on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue medication use were set to missing and missing values imputed by last observation carried forward (LOCF).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16
percent changePlacebo qwDupilumab 200 mg qw
Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16-5.8 ± 8.16-75.2 ± 8.15
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = < 0.0001 · Least squares (ls) mean difference: -69.4 · 95% CI -92.5 to -46.2Dupilumab 200 mg qw vs Placebo qw
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were considered as non-responders.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16
percentage of participantsPlacebo qwDupilumab 200 mg qw
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16037.0
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · Cochran-Mantel-Haenszel · p = = 0.0006 · Percentage difference: 37.0 · 95% CI 18.82 to 55.25Dupilumab 200 mg qw vs Placebo qw
SecondaryPercentage of Participants Who Achieved IGA Score Reduction From Baseline of ≥2 Points at Week 16

IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Participants with reduction in IGA score from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as non-responders.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved IGA Score Reduction From Baseline of ≥2 Points at Week 16
percentage of participantsPlacebo qwDupilumab 200 mg qw
Percentage of Participants Who Achieved IGA Score Reduction From Baseline of ≥2 Points at Week 163.751.9
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · Cochran-Mantel-Haenszel · p = < 0.0001 · Percentage difference: 48.1 · 95% CI 28.00 to 68.30Dupilumab 200 mg qw vs Placebo qw
SecondaryAbsolute Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16
units on a scalePlacebo qwDupilumab 200 mg qw
Absolute Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16-0.98 ± 0.398-3.64 ± 0.405
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = < 0.0001 · Ls mean difference: -2.66 · 95% CI -3.80 to -1.52Dupilumab 200 mg qw vs Placebo qw
SecondaryPercent Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Values after first rescue treatment were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16
percent changePlacebo qwDupilumab 200 mg qw
Percent Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16-8.36 ± 8.098-56.44 ± 8.248
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = = 0.0001 · Ls mean difference: -48.08 · 95% CI -71.31 to -24.85Dupilumab 200 mg qw vs Placebo qw
SecondaryAbsolute Change From Baseline in EASI Score to Week 16

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in EASI Score to Week 16
units on a scalePlacebo qwDupilumab 200 mg qw
Absolute Change From Baseline in EASI Score to Week 16-3.7 ± 2.65-25.2 ± 2.65
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = <0.0001 · Ls mean difference: -21.5 · 95% CI -29.0 to -14.0Dupilumab 200 mg qw vs Placebo qw
SecondaryAbsolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16

SCORAD was a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranged from 0 (absent disease) to 103 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16
units on a scalePlacebo qwDupilumab 200 mg qw
Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16-5.1 ± 3.60-36.4 ± 3.60
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = < 0.0001 · Ls mean difference: -31.3 · 95% CI -41.5 to -21.1Dupilumab 200 mg qw vs Placebo qw
SecondaryPercent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16

SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16
percent changePlacebo qwDupilumab 200 mg qw
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16-8.2 ± 5.41-54.8 ± 5.40
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = < 0.0001 · Ls mean difference: -46.6 · 95% CI -62.0 to -31.3Dupilumab 200 mg qw vs Placebo qw
SecondaryPercentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score ( EASI-50, EASI-75, and EASI-90 Respectively) at Week 16

EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranged from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% respectively, overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score ( EASI-50, EASI-75, and EASI-90 Respectively) at Week 16
percentage of participantsPlacebo qwDupilumab 200 mg qw
Participants with EASI-5022.277.8
Participants with EASI-7514.866.7
Participants with EASI-90033.3
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · Cochran-Mantel-Haenszel · p = < 0.0001 · Percentage difference: 55.6 · 95% CI 33.38 to 77.73
  • Placebo qw vs Dupilumab 200 mg qw · Cochran-Mantel-Haenszel · p = = 0.0001 · Percentage difference: 51.9 · 95% CI 29.59 to 74.12
  • Placebo qw vs Dupilumab 200 mg qw · Cochran-Mantel-Haenszel · p = = 0.0011 · Percentage difference: 33.3 · 95% CI 15.55 to 51.11
SecondaryPercentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16

SCORAD was a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). SCORAD-50, SCORAD-75 and SCORAD-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% respectively, overall improvement in SCORAD score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing SCORAD score at Week 16 were counted as non-responders.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16
percentage of participantsPlacebo qwDupilumab 200 mg qw
Participants with SCORAD-507.455.6
Participants with SCORAD-75011.1
Participants with SCORAD-9007.4
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · Cochran-Mantel-Haenszel · p = = 0.0002 · Percentage difference: 48.1 · 95% CI 27.0 to 69.3
  • Placebo qw vs Dupilumab 200 mg qw · Cochran-Mantel-Haenszel · p = = 0.0792 · Percentage difference: 11.1 · 95% CI -0.7 to 23.0
  • Placebo qw vs Dupilumab 200 mg qw · Cochran-Mantel-Haenszel · p = = 0.1573 · Percentage difference: 7.4 · 95% CI -2.5 to 17.3
SecondaryAbsolute Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16

POEM was a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Absolute Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16
units on a scalePlacebo qwDupilumab 200 mg qw
Absolute Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16-2.6 ± 1.34-13.1 ± 1.37
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = < 0.0001 · Ls mean difference: -10.4 · 95% CI -14.3 to -6.6
SecondaryPercent Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16

POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16
percent changePlacebo qwDupilumab 200 mg qw
Percent Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16-12.1 ± 6.18-58.3 ± 6.31
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = < 0.0001 · Ls mean difference: -46.2 · 95% CI -63.9 to -28.5
SecondaryChange From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) to Week 16

Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) to Week 16
units on a scalePlacebo qwDupilumab 200 mg qw
Change in Erythema GISS0.0 ± 0.14-0.7 ± 0.14
Change in Infiltration/Papulation GISS-0.1 ± 0.13-1.0 ± 0.13
Change in Excoriation GISS-0.3 ± 0.14-1.3 ± 0.14
Change in Lichenification GISS-0.1 ± 0.14-1.2 ± 0.14
SecondaryChanges From Baseline in GISS Cumulative Score to Week 16

Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).Values after first rescue medication use were set to missing and missing values were imputed by LOCF.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Changes From Baseline in GISS Cumulative Score to Week 16
units on a scalePlacebo qwDupilumab 200 mg qw
Changes From Baseline in GISS Cumulative Score to Week 16-0.5 ± 0.46-4.2 ± 0.46
Statistical analysis
  • Placebo qw vs Dupilumab 200 mg qw · ANCOVA · p = < 0.0001 · Ls mean difference: -3.7 · 95% CI -5.02 to -2.39

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo qw0/27 (0%)3/27 (11.1%)17/27 (63%)
Dupilumab 200 mg qw0/27 (0%)0/27 (0%)20/27 (74.1%)
Most frequent serious events
Most frequent serious events
EventPlacebo qwDupilumab 200 mg qw
Coronary artery stenosisCardiac disorders1/270/27
CholecystitisHepatobiliary disorders1/270/27
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/270/27
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlacebo qwDupilumab 200 mg qw
NasopharyngitisInfections and infestations5/273/27
Upper respiratory tract infectionInfections and infestations4/274/27
Dermatitis atopicSkin and subcutaneous tissue disorders4/274/27
Viral upper respiratory tract infectionInfections and infestations2/273/27
Conjunctivitis allergicEye disorders0/272/27
FatigueGeneral disorders1/272/27
Injection site erythemaGeneral disorders1/272/27
Injection site reactionGeneral disorders0/272/27
FolliculitisInfections and infestations0/272/27
GastroenteritisInfections and infestations0/272/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo qwDupilumab 200 mg qwTotal
Mean44.1 ± 15.7338.5 ± 13.5541.3 ± 14.81
Sex: Female, Male
Sex: Female, Male(Participants)Placebo qwDupilumab 200 mg qwTotal
Female131124
Male141630
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo qwDupilumab 200 mg qwTotal
Hispanic or Latino112
Not Hispanic or Latino252651
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo qwDupilumab 200 mg qwTotal
White201939
Black or African American336
Asian358
Other101
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(units on a scale)Placebo qwDupilumab 200 mg qwTotal
Mean34.2 ± 14.5933.4 ± 15.4133.8 ± 14.87
Investigator Global Assessment (IGA) Score
Investigator Global Assessment (IGA) Score(units on a scale)Placebo qwDupilumab 200 mg qwTotal
Mean3.5 ± 0.513.5 ± 0.513.5 ± 0.50
Weekly Peak Pruritus Numeric Rating Scale (NRS)
Weekly Peak Pruritus Numeric Rating Scale (NRS)(units on a scale)Placebo qwDupilumab 200 mg qwTotal
Mean7.4 ± 2.047.1 ± 2.427.3 ± 2.22
Global Individual Signs Score (GISS) Total Score
Global Individual Signs Score (GISS) Total Score(units on a scale)Placebo qwDupilumab 200 mg qwTotal
Mean8.9 ± 1.698.4 ± 1.828.6 ± 1.76

5 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Chicago, Illinois, United States
  • New York, New York, United States
  • Dallas, Texas, United States
  • Montreal, Quebec, Canada
09

References and documents

Publications

  • Callewaert C, Nakatsuji T, Knight R, Kosciolek T, Vrbanac A, Kotol P, Ardeleanu M, Hultsch T, Guttman-Yassky E, Bissonnette R, Silverberg JI, Krueger J, Menter A, Graham NMH, Pirozzi G, Hamilton JD, Gallo RL. IL-4Ralpha Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J Invest Dermatol. 2020 Jan;140(1):191-202.e7. doi: 10.1016/j.jid.2019.05.024. Epub 2019 Jun 25. PubMed 31252032 ↗
  • Guttman-Yassky E, Bissonnette R, Ungar B, Suarez-Farinas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019 Jan;143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5. PubMed 30194992 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Dec 2014, 12 months.

Results were first posted in Mar 2020, 5 years 2 months after primary completion. A results delay was requested in Apr 2015.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2013
First posted
Nov 8, 2013
StartActual
Dec 31, 2013
Primary completionActual
Dec 31, 2014
CompletionActual
Jan 31, 2015
Results delay requested
Apr 2, 2015
Results first posted
Mar 18, 2020
Last update
Mar 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01979016
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 8, 2013
Start date
Dec 31, 2013
Primary completion
Dec 31, 2014
Completion
Jan 31, 2015
Results posted
Mar 18, 2020
Last update
Mar 18, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion